Although there is insufficient evidence for the efficacy of fludrocortisone and midodrine for the treatment of OH in PD, it is considered to be “possibly useful” because of its proven efficacy outside of PD with some signals of efficacy detected in the PD trials.2 Recently, the norepinephrine transporter blocker atomoxetine has been shown to increase standing blood pressure and reduce the burden of OH symptoms when compared with placebo in mixed cohorts of patients with neurogenic OH.157. Here, SLC6A2 is linked to Parkinson disease.